ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

FREMONT, Calif., March 14, 2023 /PRNewswire/ -- ABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the Company based in Fremont, California, received an approval of Maitake Mushroom Dietary Supplement Tablet from Taiwan Ministry of Health and Welfare (MHW) on February 6, 2023. This approval served as an Import License (IL) for the shipment of Maitake Mushroom Tablets which have been developed and manufactured by BioKey for commercial sales in Taiwan under the brand name "DFN." BioKey is currently producing dietary supplements derived from the Maitake Mushroom in tablet and liquid forms.